Scarica l'app Stockscreener
174.90
0.43%
-0.75
Dopo l'orario di chiusura:
174.15
-0.75
-0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$175.65
Aprire:
$175
Volume 24 ore:
1.52M
Relative Volume:
0.62
Capitalizzazione di mercato:
$23.47B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-51.44
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
+7.45%
1M Prestazione:
+11.25%
6M Prestazione:
+100.62%
1 anno Prestazione:
+215.70%
Intervallo 1D:
$173.82
$179.39
Intervallo di 1 settimana:
$155.78
$179.39
Portata 52W:
$55.38
$179.39
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
174.90 | 21.12B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
648.43 | 225.48B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
208.36 | 140.70B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
345.34 | 47.41B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
268.82 | 43.09B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
153.69 | 41.42B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Guardant Health Inc Share PriceGH, RNS News, Articles, Quotes, & Charts - Proactive financial news
Guardant Health (NASDAQ: GH) officer moves to sell more stock - Stock Titan
(GH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - BioSpace
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating - investing.com
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
GH Looks 144.6% Overvalued on GF Value™ - GuruFocus
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection - Yahoo Finance
Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer - Yahoo Finance
AstraZeneca Breast Cancer Drug Etcamah Nets Accelerated FDA Approval With Guardant Health ctDNA Test - GenomeWeb
AmirAli Talasaz Reflects on Lives Lost to Colorectal Cancer – Guardant Health - Oncodaily
A Look at Guardant Health Inc (GH) After 3.4% Gain -- GF Value $65.83 vs Price $164.41 - GuruFocus
Guardant Health rises as investors weigh strong growth outlook against patent overhang - Quiver Quantitative
William Blair Maintains Guardant Health(GH.US) With Buy Rating - Moomoo
Guardant Health Shield Test to be Covered by Carelon for Colorectal Cancer Screening - GenomeWeb
Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening - Business Wire
Guardant Health, Inc. (GH) Investor Outlook: A 20% Upside Potential Amidst Rapid Revenue Growth - DirectorsTalk Interviews
Guardant Health Inc (GH) Shares Fall 4.2% -- GF Value Says Still Overvalued - GuruFocus
Don't Ignore The Insider Selling In Guardant Health - Sahm
Guardant Suits Against Tempus AI Clear Dismissal Bids - Law360
Has Guardant Health (GH) Run Too Far After Its US$245 Million Patent Ruling? - Yahoo Finance
Final judgement favours TwinStrand in Guardant patent case - pharmaphorum
Guardant ordered to pay $245m in DNA sequencing patent dispute - Yahoo Finance
Guardant Health Inc (GH) Shares Fall 4.4% -- What GF Score of 65 Tells Investors - GuruFocus
Guardant Health, Inc. (GH) Stock Analysis: A Promising Growth Potential with Strong Buy Ratings - DirectorsTalk Interviews
A court orders Guardant Health to pay $245.2M and 6% royalties through 2033 - Stock Titan
Guardant Health (NASDAQ: GH) insider plans more sales after June disposals - Stock Titan
Ninepoint Partners LP Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Gains as Investors Continue to Weigh Strong Q2 Growth and Shield Momentum - Quiver Quantitative
B of A Securities maintains Buy on Guardant Health, raises target to $190 - scanx.trade
Lisanti Capital Growth LLC Takes $1.59 Million Position in Guardant Health, Inc. $GH - MarketBeat
MSH Capital Advisors LLC Purchases Shares of 6,242 Guardant Health, Inc. $GH - MarketBeat
Eagle Health Investments LP Acquires New Position in Guardant Health, Inc. $GH - MarketBeat
How Investors Are Reacting To Guardant Health (GH) Expanding Blood-Based Cancer Screening Acceptance - simplywall.st
7,149 Shares in Guardant Health, Inc. $GH Purchased by Perigon Wealth Management LLC - MarketBeat
Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock - MarketBeat
How Guardant aims to expand cancer screening with a blood test - MedTech Dive
Guardant Health (NASDAQ: GH) insider plans August sale of 116 shares - Stock Titan
Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum - Yahoo Finance
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):